Skip to Main Content

INFORMATION FOR

    Multiple Myeloma, Phase I-II

    Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

    What is the purpose of this trial?

    The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.

    Contact Information

    For more information about this study, including how to volunteer, contact Tatiana Khorokhorina

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

    • Last Updated
      02/21/2025
    • Study HIC
      #2000028918